CD274 and neoplasm: Similarly, in the phase 1 study of atezolizumab in NSCLC patients (n = 53), best responses were observed in a specific subgroup of tumor-infiltrating immune cells with PDL-1 expression (macrophages, DCs, and lymphoid cells) (84).